Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
16 evidence topics · 13 sources
Summary
Lanifibranor is an investigational medicine that has not been approved by any regulatory authority. It is being evaluated in the phase 3 NATiV3 trial in patients with MASH with moderate and advanced fibrosis, and the manufacturer expects to report topline results in the fourth quarter of 2026. In the EASL guideline, management of MASLD consists of lifestyle modification and optimal management of comorbidities, including incretin-based therapies for type 2 diabetes or obesity, with resmetirom, if approved locally, considered as a MASH-targeted therapy for non-cirrhotic MASH with fibrosis stage 2 or higher; no MASH-targeted pharmacotherapy is recommended for the cirrhotic stage. The same guideline describes a phase IIb trial of lanifibranor with dose-dependent histological improvement of steatohepatitis and fibrosis and side effects of a 2.5% increase in weight, pedal oedema, and mild anaemia. For adults with type 2 diabetes and biopsy-proven MASH or high risk of liver fibrosis, the American Diabetes Association prefers a GLP-1 RA for glycemic management, allows pioglitazone plus a GLP-1 RA, and advises referral to a gastroenterologist or hepatologist for consideration of a thyroid hormone receptor-β agonist.
The American Diabetes Association states that MASH therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team, and the Cigna prior authorization policy for Rezdiffra requires prescribing by or in consultation with an endocrinologist, gastroenterologist, or hepatologist. About 14% of MAESTRO-NASH participants were receiving a GLP-1 RA, and the EASL guideline considers it reasonable to use resmetirom by the same criteria in these individuals; the AASLD resmetirom update states that data are insufficient to guide whether or when to start resmetirom in persons already taking therapies with potential MASH efficacy. Combination use of semaglutide 2.4 mg/week with resmetirom has not been studied, and another publication did not recommend upfront combination therapy and supported treatment consideration with resmetirom or semaglutide for noncirrhotic MASLD with liver stiffness of 10 to 20 kPa or ELF of 9.2 to 11.3. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription, mostly before resmetirom (33.8%), and 231 of the remaining 4524 (5.1%) were co-initiators.
The manufacturer describes lanifibranor as a once-daily oral therapy, plans to demonstrate its value as monotherapy and in combination, and states that NATiV3 assesses lanifibranor in combination with GLP-1 and SGLT2 inhibitors. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.
EASL-EASD-EASO treatment algorithm: lifestyle, comorbidity management, and resmetirom for non-cirrhotic MASH with fibrosis stage 2 or higher
EASL-EASD-EASO guideline on lanifibranor: phase 2b results and ongoing phase 3 trial
ADA Standards of Care 2026: GLP-1 RA, pioglitazone, and THR-β agonist placement in adults with type 2 diabetes and MASH
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: specialist initiation of MASH-targeted therapy (ADA Standards of Care 2026)
“Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment initiation and monitoring should be individualized and within the context of an interprofessional team that includes a gastroenterologist or hepatologist, consideration of individual preferences, and a careful shared-decision cost-benefit discussion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: prescriber specialty required by a national formulary prior authorization policy for resmetirom
Resmetirom in patients already receiving a GLP-1 RA (EASL-EASD-EASO)
Sequencing of resmetirom with incretin therapy, pioglitazone, or vitamin E (AASLD October 2024 update)
Combined semaglutide and resmetirom (AASLD November 2025 update)
Updated global consensus 2026: treatment initiation, upfront combination, and selection between resmetirom and semaglutide
“Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient's cardiometabolic profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
International expert panel 2026 on resmetirom and semaglutide: individualizing, switching, and combining agents
“The two agents act through complementary mechanisms: resmetirom as a liver-directed thyroid hormone receptor-beta agonist and semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a broad spectrum of metabolic effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world incretin exposure and co-initiation among US resmetirom initiators
“Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m2), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co-initiators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote